Coverage
-
June 16, 2026
A Delaware federal judge on Tuesday upheld a jury's 2023 verdict finding that Guardant Health Inc. should pay TwinStrand Biosciences Inc. $83.4 million for willfully infringing diagnostic patents, refusing to overturn or enhance the award.
2 other articles on this case.
View all »